Great stuff. Trial chugging along nicely. Whilst data is blinded, optimism grows. Nina has stated multiple times that DMX-200 was performing better than Placebo in the first interim analysis. Following that, 39 patients have rolled over into Open Label Extension Study. Nothing is guaranteed but we have every cause to be cautiously optimistic.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
54.5¢ |
Change
0.010(1.87%) |
Mkt cap ! $323.1M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 57.0¢ | 53.8¢ | $1.162M | 2.133M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 54.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.0¢ | 51808 | 2 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| DXB (ASX) Chart |